Corvus Pharmaceuticals

(NASDAQ) CRVS

Current Price$15.46

Market Cap$1.30B

Since IPO (2016)+10%

5 Year+431%

1 Year+361%

1 Month+5%

Corvus Pharmaceuticals Financials at a Glance

Market Cap

$1.30B

Revenue (TTM)

$0.00

Net Income (TTM)

$15.28M

EPS (TTM)

$-0.51

P/E Ratio

-30.52

Dividend

$0.00

Beta (Volatility)

1.16 (Average)

Dividend

$0.00

Beta (Volatility)

1.16 (Average)

Price

$15.46

Volume

Open

$15.97

Price

$15.46

Volume

Open

$15.97

Previous Close

$15.46

Daily Range

$15.45 - $16.20

52-Week Range

$3.17 - $26.95

Dividend

$0.00

Beta (Volatility)

1.16 (Average)

Price

$15.46

Volume

Open

$15.97

Previous Close

$15.46

Daily Range

$15.45 - $16.20

52-Week Range

$3.17 - $26.95

CRVS News

Stock Market Today, Jan. 20: Corvus Pharmaceuticals Surges After Positive Phase 1 Eczema Drug Data

Josh Kohn-LindquistJan 20, 2026

CRVS: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Corvus Pharmaceuticals

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Richard A. Miller, MD

Website

www.corvuspharma.com

Headquarters

South San Francisco, CA 94010, US

CRVS Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

-33%

Return on Capital

-70%

Return on Assets

-21%

Earnings Yield

-3.28%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.30B

Shares Outstanding

84.09M

Volume

Avg. Volume

1.28M

Financials (TTM)

Gross Profit

$105.00K

Operating Income

$42.97M

EBITDA

$42.97M

Operating Cash Flow

$32.80M

Capital Expenditure

$174.00K

Free Cash Flow

$32.97M

Cash & ST Invst.

$56.75M

Total Debt

$937.00K

Corvus Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$26.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$1.30B

N/A

Market Cap/Employee

$41.91M

N/A

Employees

N/A

Net Income

$12.32M

-1.7%

EBITDA

$12.19M

-50.8%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Net Cash

$55.81M

+9.8%

Accounts Receivable

$374.00K

+73.1%

Inventory

$0.00

N/A

Long Term Debt

$534.00K

-43.0%

Short Term Debt

$403.00K

+117.8%

Return on Assets

-21.49%

N/A

Return on Invested Capital

-69.60%

N/A

Free Cash Flow

$9.22M

-8.9%

Operating Cash Flow

$9.19M

-8.6%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

OLMAOlema Pharmaceuticals, Inc.

OLMAOlema Pharmaceuticals, Inc.$15.19+3.76%

KALVKalVista Pharmaceuticals, Inc.

KALVKalVista Pharmaceuticals, Inc.$26.72+0.04%

VTYXVentyx Biosciences, Inc.

VTYXVentyx Biosciences, Inc.$14.00+0.00%

ABSIAbsci Corporation

ABSIAbsci Corporation$5.95+6.06%

PRTAProthena Corporation plc

PRTAProthena Corporation plc$11.18-0.09%

RGNXREGENXBIO Inc.

RGNXREGENXBIO Inc.$10.22+10.85%

VSTMVerastem, Inc.

VSTMVerastem, Inc.$6.01+0.84%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

CTRACoterra Energy

CTRACoterra Energy$32.56-0.09%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$13.58+0.05%

NOKNokia

NOKNokia$13.19-0.02%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$71.57+0.06%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$45.59-0.06%

IRENIren

IRENIren$60.98+0.11%

SNAPSnap

SNAPSnap$6.11+0.33%

Questions About CRVS

What is the current price of Corvus Pharmaceuticals?

Corvus Pharmaceuticals is trading at $15.46 per share.

What is the 52-week range for Corvus Pharmaceuticals?

Over the past 52 weeks, Corvus Pharmaceuticals has traded between $3.17 and $26.95.

How much debt does Corvus Pharmaceuticals have?

As of the most recent reporting period, Corvus Pharmaceuticals reported total debt of $937,000.

How much cash does Corvus Pharmaceuticals have on hand?

Corvus Pharmaceuticals reported $4.58M in cash and cash equivalents in its most recent financial results.

What is Corvus Pharmaceuticals’s dividend yield?

Corvus Pharmaceuticals does not currently have a dividend yield.

Corvus Pharmaceuticals

Corvus Pharmaceuticals Financials at a Glance

CRVS News

Stock Market Today, Jan. 20: Corvus Pharmaceuticals Surges After Positive Phase 1 Eczema Drug Data

Corvus (CRVS) Q2 Loss Beats Estimates

Why Corvus Pharmaceuticals Stock Is Down Today

Why NVIDIA, Corvus Pharmaceuticals, and J.C. Penney Slumped Today

CRVS: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Corvus Pharmaceuticals

CRVS Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Corvus Pharmaceuticals Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About CRVS

What is the current price of Corvus Pharmaceuticals?

What is the 52-week range for Corvus Pharmaceuticals?

How much debt does Corvus Pharmaceuticals have?

How much cash does Corvus Pharmaceuticals have on hand?

What is Corvus Pharmaceuticals’s dividend yield?

Premium Investing Services